From
Dr. Alexander Bondoc
Intraoperative Pyloric Botulinum Toxin Injection for Post Total Pancreatectomy With Islet Autotransplantation Gastroparesis Improvement in Children
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Apr 2025 · 1 min read
In brief
In brief
This retrospective study demonstrates that intraoperative pyloric botulinum toxin injection during total pancreatectomy with islet autotransplantation significantly reduces post-operative gastroparesis in pediatric patients. Children receiving botulinum toxin achieved full oral nutrition 11 days earlier and required fewer gastrostomy tube drainage days compared to controls.
Written by the GCMD Library team from the article.
Background: Acute Recurrent Pancreatitis (ARP) and Chronic Pancreatitis (CP) may cause abdominal pain, malnutrition, opioid dependency, and impairment in quality of life. Total Pancreatectomy with Islet Autotransplantation (TPIAT) is an option when other measures fail. Pancreatitis gastroparesis can be potentiated by surgery. Botulinum toxin (BT) injections into the pylorus have been used in children for gastroparesis. We evaluated outcomes of pyloric injection of BT for TPIAT in children. Methods: Retrospective cohort of children who underwent TPIAT (2021-2023). Twenty with-BT and 20 without-BT were evaluated for time to achieve full oral nutrition, percent weight change at discharge, days with emesis through post op day 14 (POD14), days when gastrostomy tube (G) required drainage for vomiting through POD14, length of stay (LOS). We hypothesized that pyloric BT during TPIAT would decrease post-operative gastroparesis symptoms. Results: CP diagnosis present in 80 % of with-BT & 65 % of the without-BT patients. The groups were similar by sex (with-BT, 45 % male vs 50 % in without-BT). With-BT patients had fewer days to full PO (29.4 (18.3) vs. 40.9 (15.9), p < 0.01), and fewer G tube days (mean 7.2 SD (2.6) vs 10.1(3.4)) (p < 0.01) but no significant difference in emesis days (2.7 (2.8) vs 4.2 (2.9)) (p = 0.21), percent weight change at discharge (-2.9 % (2.7) vs. -4.6 % (2.7)) (p = 0.07) and LOS (median 15.5 IQR(14-16.5) vs. 16 (13.5-19)) (p = 0.46). Conclusion: Pyloric BT ma
Educational content from recorded physician discussions — not medical advice. Talk to your (or your child's) care team about your situation.
Only a few other public items share this field — go deeper there →
Article
Quality of Life Outcomes for Patients Who Underwent Conventional Resection and Liver Transplantation for Locally Advanced Hepatoblastoma
Alexander Bondoc · Published Oct 2026
Article
Pediatric Liver Transplant: Anatomic, Imaging, and Surgical Considerations-A Report of the Pediatric LI-RADS Working Group, From the AJR Special Series on Critical Anatomy
Alexander Bondoc · Published Oct 2026
Article
Customized Postoperative Therapy Improves Bile Drainage in Biliary Atresia: A Single Center Preliminary Report
Alexander Bondoc · Published Oct 2026
Article
Outcomes of Fontan patients undergoing combined heart-liver transplantation in pediatric hospitals across the United States
Alexander Bondoc · Published Oct 2026
Article
EZH2 is a key component of hepatoblastoma tumor cell growth.
Alexander Bondoc · Published Oct 2026
Article
Digestive Health Center (DHC)
Alexander Bondoc · Published Oct 2026
